Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90Yttrium-DOTA-peptide-ChL6

Prostate

Volumn 50, Issue 1, 2002, Pages 27-37

  O'Donnell, Robert T ^a   Denardo, Sally J ^a   Miers, Laird A ^a   Lamborn, Kathleen R ^a   Kukis, David L ^a   Denardo, Gerald L ^a   Meyers, Frederick J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Docetaxel; Immunotherapy; Paclitaxel; Prostate cancer; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CHIMERIC PEPTIDE L6 Y 90; CHIMERIC PROTEIN; DOCETAXEL; PACLITAXEL; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BONE MARROW TOXICITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; COMBINED MODALITY THERAPY; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PACLITAXEL; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; YTTRIUM;

EID: 0036139705     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10029     Document Type: Article

References (42)

1. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts
2. The impact of tumor cell proliferation in radioimmunotherapy
3. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression
4. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma
5. Synergistic therapy for breast cancer: Development of a clinical protocol for RIT and Taxol based on curative therapy of xenografted tumors and Y-90 ChL6 patient dosimetry
6. Concurrent paclitaxel and radiation therapy for solid tumors
7. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
8. Understanding barriers to drug delivery: High resolution in vivo imaging is key
9. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer
10. The biologic window for chimeric L6 radioimmunotherapy
11. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody
12. Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody
13. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study
14. Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody
15. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts
16. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies
17. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice
18. Yttrium-90/Indium-111-DOTA-peptide-Chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer
19. L6 monoclonal antibody binds prostate cancer
20. 90Y-DOTA-peptide-ChL6 for PC3-tumored mice
21. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells
22. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas
23. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: Development of a clinical protocol
24. Establishment and characterization of a human prostrate carcinoma cell line (PC-3)
25. Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells
26. Fas-mediated apoptosis in human prostatic carcinoma cell lines
27. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man
28. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji)
29. 131I-Lym-1 in patients with B-cell malignancies
30. 90Y-Lym-1 for Raji lymphoma xenografts
31. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus
32. Adjuvant therapy for patients with colon and rectal cancer
33. Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C
34. Chemoradiotherapy in non-small cell lung cancer: Paclitaxel/carboplatin/radiotherapy in regionally advanced disease
35. Chemotherapy plus radiotherapy compared to radiotherapy alone in the treatment of local advanced, unresectable non-small cell lung cancer
36. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
37. Apoptosis and response to radiation: Implications for radiation therapy
38. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
39. 2 arrest after DNA damage
40. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells
41. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
42. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure